TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04932005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD2269
Description: Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Part A: A single oral dose. Part C: Twice daily dosing for 7 days.
Study: NCT06285942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: To use of Edoxaban via PEG in patients with an indication to anticoagulation therapy according to current guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Edoxaban
Description: Other DOACs through PEG or subcutaneous heparin or LMWH
Study: NCT05972941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health communications
Description: Participants will view eight culturally targeted or non-targeted health communications about the health risks of nicotine and tobacco use.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health communications
Description: Participants will view eight culturally targeted or non-targeted health communications about the health risks of nicotine and tobacco use.
Study: NCT06420557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconscious Neuro-reinforcement
Description: Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 1 session of neuro-reinforcement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconscious Neuro-reinforcement
Description: Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 3 sessions of neuro-reinforcement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconscious Neuro-reinforcement
Description: Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 5 sessions of neuro-reinforcement.
Study: NCT06178523

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene Citrate.
Description: Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate.
Description: Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate.
Description: Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle (Group-A).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Insemination
Description: IUI (Group-B).
Study: NCT06594146

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 injection
Description: CM313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 injection
Description: CM313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 injection
Description: CM313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT05463744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Efsitora Alfa
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT06662461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Greater occipital nerve block
Description: Patients will be positioned in a prone position with their neck slightly flexed.~The trapezius , semispinalis, obliqus capitis muscles will be revealed on short-axis view.~A 25- or 21 gauge is used, with puncture point 1-1.5 cm away from the ultrasound probe.~Under the guidance of the ultrasound, GOB will performed by injection using 40 mg triamcinolone and 1ml of 2% lidocaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Stellate ganglion block
Description: Patients are positioned in a lateral position with their necks slightly hyperextended. Assisted by ultrasound imaging equipment the C7 level is confirmed. The thyroid gland, carotid artery, compressible internal jugular vein, vertebral artery, brachial plexus and the oval-shaped structure of the longus collis muscle are revealed on this short-axis view.~A 25- or 21 gauge is used and the puncture point is 1-1.5 cm away from the ultrasound probe The tip of the needle reach the surface of the longus collis muscle and the 5 o'clock position of the carotid artery. Under the guidance of the ultrasound, SGB is performed by injection using 40 mg triamcinolone and 1ml of 2% lidocaine.
Study: NCT06664775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TachoSil
Description: Adjunct to hemostasis

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel Original
Description: Adjunct to hemostasis
Study: NCT04068376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control excercise
Description: Each session will be for 60 minutes, 3 days a week, for 24 weeks. The make-up of each session is 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of balance-stretching exercise; and 5) 5 minutes of cool-down stretching (this times does not count as activity).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control excercise
Description: Each session will be for 60 minutes, 3 days a week, for 24 weeks. The make-up of each session is 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of balance-stretching exercise; and 5) 5 minutes of cool-down stretching (this times does not count as activity).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mind and Movement for Cognitive Health in the Older Adult
Description: The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health profesional certified to coach SSE. The make-up of each session is: 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of double-task exercise (mat); and 5) 5 minutes of cool-down stretching (this times does not count as activity).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double-task exercise by older adults and their caregivers
Description: In the case of T2-GR, older adults and their caregivers will participate in the same SSE program led by a coach for 12 weeks; older adults will then be asked to continue SSE at home under the supervision and with the active participation of their caregivers for another 12 weeks. They will be asked to practice SSE for 60 minutes, three times a week, and to reach a ≥65% heart rate increase. In the field of sports, the people who perform the above-mentioned activities are called pacers, and they supervise physical activity through active accompaniment of older adults.
Study: NCT06666335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subcutaneous injections once daily for 6 months
Study: NCT06666959

Intervention type: DRUG
Intervention: Anesthesia Agent
Description: intravenous anesthetic and inhalation anesthetic
Study: NCT06668233

Intervention type: RADIATION
Intervention: CT
Description: CT Brain

Intervention type: RADIATION
Intervention: CT scan
Description: Neuroimaging in case with delayed development , focal neurological symptoms or seziures
Study: NCT06664840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDR diet assessment
Description: Participants will record their dietary intake on the MyRareDiet (MRD) app and nutrient content will be assessed to validate MRD compared to a traditional interviewer assessed 24 hour recall.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24 hour recall
Description: A trained nutritionist will conduct a telephone multi-pass 24 hour diet recall on 3 randomized nonconsecutive days. The dietary intake will be analyzed using NDSR and metabolic pro and nutrient intake will be compared to the nutrient intake assessed with the MRD app.
Study: NCT06667180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity TMS
Description: Low-intensity TMS will be applied for 4 days, 5 daily sessions of 200 s with 10-minute intersession intervals at a field intensity of 2-4 mT and frequency of 50 Hz in theta bursts.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: The control group will receive the simulation of low-intensity TMS without magnetic field induction.
Study: NCT06294912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Description: Tablets to be administered orally as definitive antimalarial treatment.
Study: NCT06617247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention1: Cannabidiol
Description: Os cuidadores randomizados para esta intervenção usarão CBD oral 300 mg (ou seja, 150 mg, duas vezes ao dia) por quatro semanas. A substância será fornecida gratuitamente pela empresa Ease Labs e será administrada em cápsulas para promover o cegamento. Esta posologia foi baseada no estudo, no qual o CBD nesta dosagem e forma de apresentação provou ser seguro e eficaz na redução de indicadores de burnout em profissionais de saúde da linha de frente da COVID-19. A segurança do uso do CBD também foi relatada em estudos anteriores conduzidos com humanos. Os efeitos colaterais do uso do CBD são raros, incluindo sintomas leves e toleráveis (por exemplo, tontura, sonolência, fadiga, letargia, náusea, dor de cabeça, febre e alterações sensoriais).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 2: Placebo
Description: In this group, the subjects will receive placebo intervention. For blinding purposes, caregivers in this group will use the vehicle of oral CBD 300mg (
Study: NCT06666374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OHL program
Description: This program used OHL as its core structure and incorporated elements of experiential learning and self-efficacy to enhance patient engagement and understanding. The program comprised seven steps designed to guide patients through key aspects of oral health care, enabling them to progressively build their skills and confidence. These steps included personalized education on oral health, hands-on practice of proper oral hygiene techniques, self-assessment exercises, and strategies for overcoming barriers to good oral health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional program
Description: Program primarily focused on providing information without the OHL components, self-efficacy strategies, or the interactive elements of the intervention program.
Study: NCT06667544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNK08954-01
Description: Once daily oral treatment for a 3 week cycle
Study: NCT06668753

Intervention type: DRUG
Intervention: Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab
Description: SGLT-2 inhibitors
Study: NCT06450873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coriolus Versicolor Extract
Description: Dietary Supplement Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06667791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer guided sodium hyaluronate injections
Description: Patients will be treated with Computer guided sodium hyaluronate injections in superior TMJ space

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional sodiumhyaluronate injections
Description: Patients will be treated with conventional sodium hyaluronate injections in superior TMJ space
Study: NCT06620198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo® Power 2 Exoskeleton - Active Rehabilitation with Feedback and Exercise Gaming
Description: Patients will undergo 20 session of 45 minutes each with an exoskeleton for upper limb rehabilitation. The assistance provided by the device is adjusted based on the maximum force (as a percentage of the upper limb's weight) the robot needs to exert to assist the patient's movements. Each session will include exercises designed to improve the range of motion (ROM) of the shoulder, elbow, wrist, and enhance hand coordination. The training parameters, such as difficulty level, duration, and visual stimuli, will be adjusted based on the patient's residual abilities. The selected exercises may involve movements of a single joint along one axis, combined movements of a single joint around 2 or 3 axes, selective exercises for the opening and closing hand, or multi-joint exercises. All exercises will be realized with audiovisual feedback.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Armeo® Power 2 Exoskeleton - Passive Mobilization without Feedback
Description: Patients will undergo 20 session of 45 minute of a neurorehabilitation intervention with a SHAM treatment under the guidance of the experimental therapist. This will involve passive mobilization using the exoskeleton for the upper limb, without any audiovisual feedback. They will not realize any active movement during the training.
Study: NCT06294912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Description: Tablets to be administered orally as definitive antimalarial treatment.
Study: NCT06621940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: Individuals will be placed on a high protein diet for 10 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Protein Diet
Description: Individuals will be placed on a normal protein diet for 10 days.
Study: NCT06621615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVL006 Injection
Description: CVL006 injection, intravenous infusion, administered every 2 weeks. Every 28 days is a cycle. Until the subject cannot tolerate the disease progression or toxicity, or the researcher determines that the medication must be terminated or the sponsor terminates the study. SMC can adjust the dosing frequency based on safety, tolerability, and PK results data. If researchers consider that subjects enrolled in the lower dose group can benefit from the study intervention, they can allow them to continue treatment at a higher dose that has been proven safe based on the researcher's judgment.
Study: NCT06619041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthyTogether
Description: HealthyTogether is a brief (8-session), virtual, dyadic weight management intervention.
Study: NCT06620120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: At the D0 visit, if the patient is assigned to the arm with insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without insoles
Description: At the D0 visit, if the patient is assigned to the arm without insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm.
Study: NCT06619197

Intervention type: OTHER
Group type: OTHER
Intervention: Global reflexology
Description: The EMC method is a global reflexology technique inspired by the work of the American naturopath Stanley Burrough (Vitaflex, 1976). It is a method of reflexology on the whole body, of acupressure massages (rhythmic and targeted movements) on so-called \&#34;reflex\&#34; zones which is practiced on different areas of the body (feet, hands, arms, legs, collarbone, ear) and allows the stimulation of all systems.
Study: NCT06620952

Intervention type: PROCEDURE
Intervention: O-ring technique
Description: O-ring technique. consists on a different arrangement of fibrin-glue on a polymethilmetacrylate cranioplasty, with the aim to create a gasket to prevent CSF leakage
Study: NCT06667882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase Injectable Product
Description: The 2019 ESC guideline for the diagnosis and management of acute pulmonary embolism (PE) recommended thrombolytic therapy only in high-risk PE cases because of the bleeding risk. The most often used drug for thrombolysis is the rtPA and the recommended dose is 100 mg over two hours. According to the literature, the risk of major haemorrhage is 10-13% and fatal or intracranial bleeding is 1.7-3.6% among patients receiving thrombolysis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase Injectable Product
Description: The 2019 ESC guideline for the diagnosis and management of acute pulmonary embolism (PE) recommended thrombolytic therapy only in high-risk PE cases because of the bleeding risk. The most often used drug for thrombolysis is the rtPA and the recommended dose is 100 mg over two hours. According to the literature, the risk of major haemorrhage is 10-13% and fatal or intracranial bleeding is 1.7-3.6% among patients receiving thrombolysis.
Study: NCT05318534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GL-0719
Description: Administration route: intravenous infusion and subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration route: intravenous infusion and subcutaneous injection
Study: NCT06665997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Description: 150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension
Study: NCT06667817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16 weeks of exercise training (Exercise Group) will be prescribed via a smart phone application. Results from this group will be compared to results of the sedentary control group.
Study: NCT05592847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Navigator Program
Description: Identification of specific chronic conditions and suggestion of management care of primary care physicians and referrals to specialists via nurse navigator team members.
Study: NCT06624306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone PNL
Description: Prone PNL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone-flexed PNL
Description: Prone-flexed PNL
Study: NCT04157114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAP4343
Description: Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized behavioral counseling
Description: Subjects receive manually-guided counseling 1 time per week for a 6 week duration

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standardized behavioral counseling
Description: Subjects receive manually-guided counseling 1 time per week for a 6 week duration
Study: NCT05590637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimavanserin
Description: Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
Study: NCT05349721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC857
Description: PTC8657 will be administered as an oral solution twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as an oral solution twice a day.
Study: NCT06152016

Intervention type: OTHER
Group type: OTHER
Intervention: BE-FAST
Description: This intervention includes those randomized to the education with the BE-FAST mnemonic.

Intervention type: OTHER
Group type: OTHER
Intervention: FAST
Description: This intervention includes those randomized to the education with the FAST mnemonic.
Study: NCT05130255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GD2-SADA:177Lu-DOTA Complex
Description: The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA, both will be administered as an IV infusion
Study: NCT05304715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezlotoxumab
Description: Single intravenous infusion of bezlotoxumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9% or 5% dextrose water
Description: Single intravenous infusion - Placebo arm